GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
D

DuoGenic StemCells 7607.TWO · TWD

Health Care · Taipei Exchange · 🇹🇼 Taiwan

Compare

11.80

-1.26%

Close of 9 Nov 2026, in TWD

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About DuoGenic StemCells

Its shares trade on Taipei Exchange under the ticker 7607.TWO. It has been listed since 25 May 2023. In the fiscal year to 31 December 2024, it reported revenue of TWD 12.1m and a net loss of TWD 61.6m. At that date it held total assets of TWD 59.7m and shareholders' equity of TWD 16.8m.

Duogenic Stemcells Corp. engages in the provision of biotechnology and medical care services. The company is headquartered in Taichung, Taichung. The company went IPO on 2023-05-25. The firm's products include cell separator sets and culture media. The firm also provides various customized cell testing services, product certification and technical consulting services on a consignment basis.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Life Sciences Tools & Services
Listed since
25 May 2023
Website
dgsc.com.tw ↗

Leadership

Pay as last reported

  • Yuyu RaoHead of Accounting
  • Shunu KeIndependent Director
  • Ms. Aij-lie KwanIndependent Director
  • Mr. Tay-Ing LiaowIndependent Director

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Headquartered in Taichung, Taiwan, providing biotechnology and medical care services.
  • Offers cell separator sets and culture media as core products.
  • Provides customized cell testing services and technical consulting on a consignment basis.

Weaknesses

  • IPO occurred in 2023, indicating limited market history.
  • Operates in a specialized sector with potential market saturation.
  • Relies on consignment basis for technical consulting services.

Opportunities

  • Growth potential in the Life Sciences Tools & Services sector.
  • Expanding biotechnology market in Taiwan and globally.
  • Increasing demand for cell-based medical services and products.

Threats

  • Competition from established players in the biotechnology sector.
  • Regulatory challenges in the healthcare and biotechnology industries.
  • Dependence on consignment-based service model for revenue.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.